A Feasibility Study on the Safety and Preliminary Efficacy of Bilateral Subthalamotomy Using MRgFUS for Treatment of PD
A Feasibility Study on the Safety and Preliminary Efficacy of Bilateral Subthalamotomy Using the ExAblate Transcranial System to Treat the Cardinal Motor Features of Parkinson's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Madrid
-
Móstoles, Madrid, Spain, 28938
- Hospital Universitario HM Puerta Del Sur. CINAC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or Female age 30 years or older
- Able and willing to give consent and able to attend all study visits
- A confirmed diagnosis of Parkinsons Disease
- Subjects that have received unilateral subthalamotomy at least 6 month before the inclusion in bilateral subthalamotomy and present parkinsonian symptoms
- Able to localize subthalamic nucleus on MRI for treatment
- Able to communicate sensations during the ExAblate MRgFUS procedure
Exclusion Criteria:
- Hoehn and Yahr stage in the ON medication state of 2.5 or greater
- Presence of severe dyskinesia as noted by MDS-UPDRS scores
- Presence of other central neurodegenerative disease
- Parkinsonian symptoms are a side effect from neuroleptic medications
- Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse
- History of a bleeding disorder or receiving anticoagulant
- Subjects with advanced kidney disease or on dialysis
- Subjects with known intolerance or allergies to the MRI contrast agents.
- Presence of unknown or MRI unsafe devices anywhere in the body.
- History of multiple strokes, or a stroke within past 6 months
- Subjects with a history of seizures within the past year
- Subjects with malignant brain tumors
- Women who are pregnant or nursing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ExAblate 4000 System
Exablate bilateral treatment for Parkinson's Disease Motor Features
|
Exablate bilateral treatment for Parkinson's Disease Motor Features
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety: Adverse Events
Time Frame: Treatment through 6 month
|
To evaluate the incidence and severity of adverse events (AE/AEs) associated with ExAblate subthalamotomy for the treatment of PD motor features.
|
Treatment through 6 month
|
|
Primary Efficacy: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Off Medication Status
Time Frame: Treatment through 6 month
|
Effectiveness of the ExAblate Transcranial staged bilateral subthalamotomy by analyzing mean change (reduction from baseline to 6 months) in the motor MDS-UPDRS score in the treated group as compared with baseline in the off-medication condition
|
Treatment through 6 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) On Medication Status
Time Frame: Treatment through 6 month
|
- Mean change (reduction) in the motor MDS-UPDRS score in the on-medication condition (when applicable)
|
Treatment through 6 month
|
|
MDS-UPDRS
Time Frame: Treatment through 12 month
|
- Mean change (reduction) in specific PD motor features (i.e., tremor, rigidity and akinesia according to MDS-UPDRS III subscores)
|
Treatment through 12 month
|
|
MDS-UPDRS (Part I, II and IV)
Time Frame: Treatment through 6 month
|
MDS UPDRS I, II and IV
|
Treatment through 6 month
|
|
Quality of life assessment
Time Frame: Treatment through 6 month
|
Improved Quality of life assessment with the PDQ39
|
Treatment through 6 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Raul Martinez, MD, CINAC-Hospital HM Puerta del Sur
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PD010B
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.